Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis

Thrombosis Research

Volumn 126, Issue 1, 2010, Pages

  Kwasny Krochin, Beata ^a   Gluszko, Piotr ^a   Undas, Anetta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Fibrin clot; Fibrinolysis; Isoprostane; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; D DIMER; FIBRIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR; PROSTAGLANDIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; HUMAN CELL; MALE; MULTIPLE REGRESSION; OXIDATIVE STRESS; PERMEABILITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCANNING ELECTRON MICROSCOPY; SEX DIFFERENCE; THROMBOCYTE COUNT; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHEMISTRY; COMPLICATION; INFLAMMATION; MIDDLE AGED; THROMBOSIS; YOUNG ADULT;

ADULT; AGED; BLOOD COAGULATION TESTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PERMEABILITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 77953123808     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.04.007     Document Type: Article

References (33)

1. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., and Gabriel S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52 (2005) 722-732
2. Van Doornum S., McColl G., and Wicks I.P. Accelerated atherosclerosis; an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 4 (2002) 862-873
3. Van Leuven S.I., Franssen R., Kastelein J.J., Stroes E.S., and Tak P.P. Systemic inflammation as a risk factor for atherothrombosis. Rheumatol (Oxford) 47 (2008) 3-7
4. Kamper E.F., Kopeeikina L.T., Trontzas P., Potamiaunou A., Tsiroglou E., and Stavridis J.C. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis. J Rheumatol 27 (2000) 2545-2550
5. Dixon W.G., and Symmons D.P.M. What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF alfa in cardiovascular pathophysiology. Ann Rheum 66 (2007) 1132-1136
6. McEntergart A., Capell H.A., Creran A., Rumley A., Woodward M., and Lowe G.D. Cardiovascular risk factors including thrombotic variables in a population with rheumatoid arthritis. Rheumatology 40 (2001) 640-644
7. So A.K., Varisco P.A., Kemkes-Matthes B., Herkenne-Morard C., Chobaz-Pechet V., Gerster J.C., and Busso N. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1 (2003) 2510-2515
8. Wållberg- Jonsson S., Cvetkovic J.T., Sundqvist K.G., Lefvert A.K., and Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. Rheumatology 5 (2002) 875-882
9. Beygui F., Collet J.P., Nagaswami C., Weisel J.W., and Montalescot G. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction. Time makes the difference. Circulation 113 (2006) e21-e23
10. Scott E.M., Ariëns R.A.S., and Grant P.J. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol 24 (2004) 1558-1566
11. Fatah K., Silveira A., Tornvall P., Karpe F., Blombäck M., and Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at young age. Thromb Haemost 76 (1996) 535-540
12. Collet J.P., Allali Y., Lesty C., Tanguy M.L., Silvain J., Ankri A., Blanchet B., Dumaine R., Gianetti J., Payot L., Weisel J.W., and Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26 (2006) 2567-2573
13. Undas A., Szuldrzynski K., Stepien E., Zalewski J., Godlewski J., Tracz W., Pasowicz M., and Zmudka K. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196 (2008) 551-557
14. Undas A., Plicner D., Stepien E., Drwila R., and Sadowski J. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost 5 (2007) 1988-1990
15. Arnett F.C., Edworthy S.M., and Bloch D.A. DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for classification of Rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
16. Prevoo M.L. van't Hof MA, Kuper IH, van Leeuwen MA, van de Putte LP, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Developement and validation in prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
17. Bruce B., and Fries J.F. The Standford Health Assessment Questionnaire: Dimensions and Practical Applications. Health Qual Life Outcomes 1 (2003) 20
18. Mills J.D., Ariens R.A., Mansfield M.W., and Grant P.J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106 (2002) 1938-1942
19. Collet J.P., Mishal Z., Lesty C., Mirshahi M., Peyne J., Baumelou A., et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost 82 (1999) 1482-1489
20. Undas A., Zawilska K., Ciesla-Dul M., Lehmann-Kopydłowska A., Skubiszak A., Ciepłuch K., and Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114 (2009) 4272-4278
21. Fatah K., Hamsten A., Blombäck B., and Blombäck M. Fibrin gel network characterisitics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase proteins, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 68 (1992) 130-135
22. Undas A., Slowik A., Wolkow P., Szczudlik A., and Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res (2009) Nov.25
23. Salonen E.M., Vartio T., Hedman K., and Vaheri A. Binding of fibronectin by the acute phase C-reactive protein. J Biol Chem 259 (1984) 1496-1501
24. Amelot A.A., Tagzirt M., Ducouvret G., Kuenk L., and Le Bonniec B.H. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J Biol Chem 282 (2007) 710-720
25. Wohner N. A role of cellular elements in thrombus formation and dissolution. Cardiovasc Hematol Agents Med Chem 6 (2008) 224-228
26. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariens RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood in press, doi:10.1182/blood-2009-11-254029.
27. Kopeikina L.T., Kamper E.F., Koutsoukos V., Bessiakos Y., and Stavridis J.C. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol 16 (1997) 254-260
28. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 131 (2005) 417-430
29. Patrono C., Falco A., and Davi G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 5 (2005) 198-203
30. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem 6 (2008) 161-180
31. Hitchon C.A., and El-Gabalawy H.S. Oxidation in rheumatoid arthritis. Arthritis Res Ther 6 (2004) 265-278
32. Undas A., Podolec P., Zawilska K., Pieculewicz M., Jedliński J., Stepien E., et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischaemic stroke. Stroke 40 (2009) 1499-1501
33. Undas A., Kolarz M., Kopec G., and Tracz W. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 23 (2008) 2010-2015